論文

査読有り
2018年6月15日

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.

Internal medicine (Tokyo, Japan)
  • Tetsuaki Shoji
  • ,
  • Hidenori Mizugaki
  • ,
  • Yasuyuki Ikezawa
  • ,
  • Megumi Furuta
  • ,
  • Yuta Takashima
  • ,
  • Hajime Kikuchi
  • ,
  • Houman Goudarzi
  • ,
  • Hajime Asahina
  • ,
  • Junko Kikuchi
  • ,
  • Eiki Kikuchi
  • ,
  • Jun Sakakibara-Konishi
  • ,
  • Naofumi Shinagawa
  • ,
  • Ichizo Tsujino
  • ,
  • Masaharu Nishimura

57
12
開始ページ
1769
終了ページ
1772
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2169/internalmedicine.9741-17

This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.

リンク情報
DOI
https://doi.org/10.2169/internalmedicine.9741-17
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29434159
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047974

エクスポート
BibTeX RIS